Targeted tumor killing via an intracellular antibody against erbB-2.
Open Access
- 1 December 1995
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 96 (6) , 2980-2989
- https://doi.org/10.1172/jci118370
Abstract
Specific killing of erbB-2-overexpressing tumor cells can be achieved using expression of an intracellular antibody directed against the erbB-2 oncoprotein. We have developed a strategy using a recombinant adenovirus encoding an anti-erbB-2 single chain antibody to achieve targeted tumor cell killing in vivo and can show significantly prolonged survival of animals carrying a human ovarian carcinoma tumor burden within their peritoneal cavities. This strategy of gene therapy for ovarian carcinoma offers the potential to achieve highly specific, targeted killing of human tumor cells and thus establishes the rationale to undertake human clinical trials on this basis.Keywords
This publication has 44 references indexed in Scilit:
- Targeted Eradication of Ovarian Cancer Mediated by Intracellular Expression of Anti-erbB-2 Single-Chain AntibodyGynecologic Oncology, 1995
- H‐ras Ribozyme‐Mediated, Alteration of the Human Melanoma PhenotypeaAnnals of the New York Academy of Sciences, 1994
- Reduction of erbB2 Gene-Product in Mamma Carcinoma Cell Lines by erbB2 mRNA-Specific and Tyrosine Kinase Consensus Phosphorothioate Antisense OligonucleotidesBiochemical and Biophysical Research Communications, 1994
- Establishment and Characterization of Mouse‐Human Chimeric Monoclonal Antibody to erbB‐2 ProductJapanese Journal of Cancer Research, 1994
- Gene Therapy for B-cell Lymphoma in a SCID Mouse Model using an Immunoglobulin-Regulated Diphtheria Toxin Gene Delivered by a Novel Adenovirus-Polylysine ConjugateCancer Biotherapy, 1994
- Triplex formation inhibits HER-2/neu transcription in vitro.Journal of Clinical Investigation, 1993
- Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the her‐2/neu oncogeneInternational Journal of Cancer, 1991
- Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB GeneScience, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985